【脉铂医药】MedBio|1316755-16-4|奥洛立更技术资料

2022-07-13

1、奥洛立更用途：
EMA401是一个高选择性的AT2R拮抗剂，能够抑制p38和p42/p44 MAPK激活引起的AngII/AT2R的增加，能够抑制DRG神经元兴奋过度。

2、奥洛立更物理化学性质：

密度	1.3±0.1 g/cm3
沸点	745.3±60.0 °C at 760 mmHg
分子式	C₃₂H₂₉NO₅
分子量	507.576
闪点	404.5±32.9 °C
精确质量	507.204559
LogP	5.98
蒸汽压	0.0±2.6 mmHg at 25°C
折射率	1.631

3、奥洛立更生物活性：

描述	Olodanrigan (EMA401) 是一个高选择性的AT2R拮抗剂，能够抑制p38和p42/p44 MAPK激活引起的AngII/AT2R的增加，能够抑制DRG神经元兴奋过度。
相关类别	血管紧张素受体
溶解度	体外： DMSO：≥34mg / mL（66.98 mM） * “≥”表示可溶，但饱和度未知。
SMILES	O=C([C@H]1N(C(C(C2=CC=CC=C2)C3=CC=CC=C3)=O)CC4=C(C(OCC5=CC=CC=C5)=C(OC)C=C4)C1)O

4、奥洛立更参考文献：

[1]. Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.Lancet. 2014 May 10;383(9929):1637-47.

[2]. Anand U et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015 Jun 26;11:38.

[3]. Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.Lancet. 2014 May 10;383(9929):1637-47.

5、奥洛立更英文别名：

3-Isoquinolinecarboxylic acid, 2-(2,2-diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-, (3S)-

(3S)-5-(Benzyloxy)-2-(diphenylacetyl)-6-methoxy-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid

EMA401

(3S)-5-(benzyloxy)-2-(diphenylacetyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid

P0FN522VTO

olodanrigan

货号	产品名称	品牌	规格型号	包装	目录价
MED24458	EMA401 ,1316755-16-4	MedBio	≥98%	10mg	¥3080.00
MED24458	EMA401 ,1316755-16-4	MedBio	≥98%	25mg	¥6160.00
MED24458	EMA401 ,1316755-16-4	MedBio	≥98%	5mg	¥1882.00